This double-blind cross-over study of 14 severely spastic inpatients with chronic multiple sclerosis reveals that once-daily doses of ketazolam, a new drug, are effective in reducing spasticity in a significant proportion of patients without significant side-effects. Added to the similar findings of an earlier double-blind controlled study of divided doses, the results suggest that this special feature of ketazolam provides a unique flexibility that may be exploited in individual cases.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
double-blind cross-over
8
cross-over study
8
ketazolam daily
4
daily spasticity
4
spasticity double-blind
4
study double-blind
4
study severely
4
severely spastic
4
spastic inpatients
4
inpatients chronic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!